Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer

被引：4
|
作者：
Guarducci, Cristina
Cristea, Simona
Feit, Avery
Naumenko, Sergey
Nardone, Agostina
Ma, Wen
Russo, Douglas
Feit, Gabriella Cohen
Feiglin, Ariel
Hermida-Prado, Francisco
Sherman, Shira
Brown, Myles
Michor, Franziska
Jeselsohn, Rinath
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-GS3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER plus breast cancer
    Mao, Pingping
    Kusiel, Justin
    Cohen, Ofir
    Wagle, Nikhil
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
    Pandey, Kamal
    An, Hee-Jung
    Kim, Seung Ki
    Lee, Seung Ah
    Kim, Sewha
    Lim, Sun Min
    Kim, Gun Min
    Sohn, Joohyuk
    Moon, Yong Wha
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1179 - 1188
  • [23] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [24] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [25] Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [27] CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer
    Cetin, Bulent
    Wabl, Chiara A.
    Gumusay, Ozge
    FUTURE ONCOLOGY, 2022, 18 (09) : 1143 - 1157
  • [28] Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
    Guarducci, Cristina
    Bonechi, Martina
    Boccalini, Giulia
    Benelli, Matteo
    Risi, Emanuela
    Di Leo, Angelo
    Malorni, Luca
    Migliaccio, Ilenia
    BREAST CARE, 2017, 12 (05) : 304 - 308
  • [29] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
    Lee, Nathan V.
    Yuan, Jing
    Eisele, Koleen
    Cao, Joan Q.
    Painter, Cory L.
    Chionis, John
    Liu, Chaoting
    Shields, David J.
    Kan, Julie L. C.
    Arndt, Kim
    VanArsdale, Todd
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Identification of distinct and targetable mechanisms of acquired resistance to CDK4/6 inhibitors
    Parsons, Stephen
    CANCER RESEARCH, 2019, 79 (13)
12345